Amicus Therapeutics Inc

Amicus Therapeutics — Q1 2025 Earnings Presentation

27 slides from Amicus Therapeutics's earnings presentation, May 1, 2025

  1. Slide 1: 1Q25 Results Conference Call & Webcast

    AT T H E F O R E F R O N T O F THERAPIES FOR RARE DISEASES 1Q25 Results Conference Call & Webcast May 1, 2025

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercialization plans, manufacturing

  3. Slide 3: A Rare Company

    A Rare Company A unique story in biotech with significant revenue growth and profitability First Two- 10-15% 50-65% First Oral Component Therapy Precision for Pompe Disease Medicine for Fabry Disease FY 2025 FY 2025 Galafold Revenue Pombiliti + Opfolda Growth1 Revenue Growth1 $125M Expanded Portfoli

  4. Slide 4: Galafold Continued Growth

    Galafold ® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 4

  5. Slide 5: 2025 Galafold Success (as of March 31, 2025)

    2025 Galafold Success (as of March 31, 2025) Only approved oral treatment in Fabry disease and standard of care for amenable patients A unique mechanism of action for Fabry patients with amenable variants $104.2M 1Q25 Galafold 69% Revenue +14% 1Q25 Galafold Share of Treated Patient Demand Amenable P

  6. Slide 6: Galafold Performance

    Galafold Performance 1Q 2025 Galafold reported revenue of $104.2M (+6% growth at CER) +10-15%1  Quarterly patient starts remains strong: +14% $458M growth in 1Q YoY2 Q4  1Q revenue impacted by ordering patterns and $388M $128M greater than anticipated U.K. rebate $329M $306M  Global mix of naïve

  7. Slide 7: Pombiliti + Opfolda

    Pombiliti® (cipaglucosidase alfa-atga) + ® Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 7

  8. Slide 8: Pombiliti + Opfolda Performance

    Pombiliti + Opfolda Performance 1Q 2025 Pombiliti + Opfolda reported revenue of $21.0M (+92% at CER)  Strong 1Q sales growth YoY, particularly in the U.S. +50-65%1 – Number of net new patients continues to grow – Increasing depth and breadth of prescribers  1Q 2025 revenue reflected timing of pati

  9. Slide 9: Pombiliti + Opfolda Expansion

    Pombiliti + Opfolda Expansion 3 regulatory approvals and up to 10 new launch countries in 2025 Regulatory Regulatory approvals anticipated in 2025:  Recently approved in Australia and Canada  Regulatory approval in Japan anticipated in 2025 AUSTRALIA CANADA JAPAN Combined ~150-200 people 18+ livin

  10. Slide 10: Supply Chain

    Supply Chain Ensuring access to our two medicines through supply chain planning Limited Tariff Impact Diversifying Supply Chain  Anticipate no material impact to P&L or business  New commercial manufacturing and supply services operations in 2025 of any of the proposed tariffs: agreement in place

  11. Slide 11: Pombiliti + Opfolda Body of Evidence

    Pombiliti + Opfolda Body of Evidence Growing number of abstracts, manuscripts, and case studies supporting Pombiliti + Opfolda differentiation Clinical Trials & Long-Term Data  Long-term Phase 1/2 open-label safety and efficacy study (ATB200-02)  104-week Phase 3 open-label extension study of effi

  12. Slide 12: DMX-200

    DMX-200 Potential first-in-class investigational small molecule for the treatment of FSGS in the U.S. 12

  13. Slide 13: Exclusive U.S. License Agreement with Dimerix

    Exclusive U.S. License Agreement with Dimerix Deal adds significant value to Amicus today and aligns with Amicus strategy to leverage our rare disease commercial infrastructure with promising late-stage program 1 Focal Segmental Glomerulosclerosis (FSGS) is a rare and fatal kidney disease1 that aff

  14. Slide 14: DMX-200 Transaction Summary

    DMX-200 Transaction Summary License agreement is heavily weighted to mutually beneficial success-based milestones Upfront investment of $30M paid with cash on hand Up to $560M in potential success-based milestone payments  Up to $75M in development & regulatory milestones until FDA approval of DMX-

  15. Slide 15: Focal Segmental Glomerulosclerosis (FSGS) is a rare disease leading to irreversible kidney damage

    Focal Segmental Pathogenic Feedback Glomerulosclerosis (FSGS) Loop in FSGS is a rare disease leading to DMX-200 irreversible kidney damage Existing blood pressure specifically blocks kidney medication targets inflammatory signaling angiotensin receptor blocker (ARB) lowers Kidney vessels have to wor

  16. Slide 16: Dimerix has built a strong body of evidence with DMX-200 in FSGS

    Dimerix has built a strong body of evidence and made significant clinical and regulatory progress with DMX-200 in FSGS Precision therapy to disrupt the pathogenic monocyte-driven inflammatory feedback MOA loop in the kidney of patients with FSGS Positive efficacy signals and well-tolerated across st

  17. Slide 17: DMX-200 Phase 3 Clinical Trial in FSGS

    DMX-200 Phase 3 Clinical Trial in FSGS FDA aligned on proteinuria endpoint for approval; 185 patients already randomized/dosed to date A randomised, double-blind, multi-center, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Background Phase 3 Trial Timel

  18. Slide 18: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 18

  19. Slide 19: Q1 2025 Select Financial Results

    Q1 2025 Select Financial Results Q1 2025 revenue of $125M, up 15% at CER and non-GAAP net income of $9.0M Q1’25 Mar. 31, 2025 Mar. 31, 2024 (in thousands, except per share data) Net product sales $ 125,249 $ 110,403 Cost of goods sold 11,698 13,567 GAAP operating expenses 121,503 124,557 Non-GAAP op

  20. Slide 20: FY 2025 Financial Guidance

    FY 2025 Financial Guidance FY 2025 Financial Guidance1 Previous Guidance Updated Guidance Total Revenue Growth1 17% to 24% 15% to 22% Galafold Revenue Growth1 10% to 15% 10% to 15% FY 2025 Revenue Sensitivity Given the proportion of Amicus revenue ex-US Pombiliti + Opfolda Revenue Growth1 65% to 85%

  21. Slide 21: 2025 Strategic Priorities

    2025 Strategic Priorities Deliver total revenue growth of 15-22% at CER1 Double-digit Galafold® revenue growth of 10-15% at CER1 Pombiliti®+ Opfolda® revenue growth of 50-65% at CER1 Advance ongoing studies in Fabry, Pompe and now FSGS Deliver positive GAAP net income during H2 2025 21 1 CER: Consta

  22. Slide 22: A Rare Company

    A Rare Company A unique story in biotech with significant revenue growth and profitability Surpassing $1B in Total Sales Double-digit in 2028 Leverageable Revenue Rare Disease Growth Infrastructure Two Approved Self- Therapies Sustainable Company and One Late Stage Growing Free Phase 3 Program Cash

  23. Slide 23: Appendix

    Amicus Therapeutics Appendix

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    Reconciliation of Non-GAAP Financial Measures 24

  25. Slide 25: Reconciliation of Non-GAAP Financial Measures (Cont’d)

    Reconciliation of Non-GAAP Financial Measures (Cont’d) 25

  26. Slide 26: Exchange Rates

    Exchange Rates Currency Average Rates FX Rates Q1 2024 Q1 2025 Variance USD/EUR 1.086 1.052 (3.1%) USD/GBP 1.268 1.259 (0.7%) USD/JPY 0.007 0.007 (2.7%) 26

  27. Slide 27: Rare Disease Pipeline

    Rare Disease Pipeline INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FA B R Y D I S E A S E Galafold® (migalastat) Fabry Genetic Medicines POMPE DISEASE Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Pompe Genetic Medicines RARE KIDNEY DISEASE DMX-200 in Foca

Amicus Therapeutics — Q1 2025 Earnings Presentation on 6ix